227 related articles for article (PubMed ID: 34019661)
1. A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial.
Pencina KM; Burnett AL; Storer TW; Guo W; Li Z; Kibel AS; Huang G; Blouin M; Berry DL; Basaria S; Bhasin S
J Clin Endocrinol Metab; 2021 Jul; 106(8):2171-2186. PubMed ID: 34019661
[TBL] [Abstract][Full Text] [Related]
2. Testosterone replacement in prostate cancer survivors with testosterone deficiency: Study protocol of a randomized controlled trial.
Valderrábano RJ; Pencina K; Storer TW; Reid KF; Kibel AS; Burnett AL; Huang G; Dorff T; Privat F; Ghattas-Puylara C; Wilson L; Latham NK; Holmberg M; Bhasin S
Andrology; 2023 Jan; 11(1):93-102. PubMed ID: 36181480
[TBL] [Abstract][Full Text] [Related]
3. Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Gacci M; Corona G; Apolone G; Lanciotti M; Tosi N; Giancane S; Masieri L; Serni S; Maggi M; Carini M
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):168-72. PubMed ID: 20212520
[TBL] [Abstract][Full Text] [Related]
4. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
5. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
6. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.
Ilic D; Evans SM; Allan CA; Jung JH; Murphy D; Frydenberg M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009625. PubMed ID: 28895658
[TBL] [Abstract][Full Text] [Related]
7. Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy.
Montorsi F; Oelke M; Henneges C; Brock G; Salonia A; d'Anzeo G; Rossi A; Mulhall JP; Büttner H
Eur Urol; 2016 Sep; 70(3):529-37. PubMed ID: 26947602
[TBL] [Abstract][Full Text] [Related]
8. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
[TBL] [Abstract][Full Text] [Related]
9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
10. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
[TBL] [Abstract][Full Text] [Related]
11. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y
Int J Urol; 1999 May; 6(5):229-37; discussion 238-9. PubMed ID: 10375185
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
13. Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.
D'Amico AV; Chen MH; Malkowicz SB; Whittington R; Renshaw AA; Tomaszewski JE; Samofalov Y; Wein A; Richie JP
J Urol; 2002 May; 167(5):2025-30; discussion 2030-1. PubMed ID: 11956431
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
15. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy.
Mulhall JP; Klein EA; Slawin K; Henning AK; Scardino PT
J Sex Med; 2018 Sep; 15(9):1293-1299. PubMed ID: 30224019
[TBL] [Abstract][Full Text] [Related]
19. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.
Basaria S; Collins L; Dillon EL; Orwoll K; Storer TW; Miciek R; Ulloor J; Zhang A; Eder R; Zientek H; Gordon G; Kazmi S; Sheffield-Moore M; Bhasin S
J Gerontol A Biol Sci Med Sci; 2013 Jan; 68(1):87-95. PubMed ID: 22459616
[TBL] [Abstract][Full Text] [Related]
20. Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial.
Bosland MC; Kato I; Zeleniuch-Jacquotte A; Schmoll J; Enk Rueter E; Melamed J; Kong MX; Macias V; Kajdacsy-Balla A; Lumey LH; Xie H; Gao W; Walden P; Lepor H; Taneja SS; Randolph C; Schlicht MJ; Meserve-Watanabe H; Deaton RJ; Davies JA
JAMA; 2013 Jul; 310(2):170-8. PubMed ID: 23839751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
